Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-MH-22-230

Understanding the role of Gut Immune dysfunction and Gut Microbiome in pathogenesis of Central Nervous System co-morbidities in people living with HIV (R21 Clinical Trial Not Allowed)

Closed on November 18, 2022.

Posted
April 25, 2022
Close date
November 18, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $492,992 in first-year total cost, median $492,992.

Most frequent study sections

  1. Special Emphasis Panel[ZMH1 ERB-L (05)]1

Most frequent institutions

  1. HENRY M. JACKSON FDN FOR THE ADV MIL/MED1
Competing awards under RFA-MH-22-230 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Determining the interplay of MAIT cells and the translocated microbiome in HIV-induced neuroinflammation1R21MH134244-01CORLEY, MICHAEL JAYPAQUIN-PROULX, DOMINICHENRY M. JACKSON FDN FOR THE ADV MIL/MED, MD$492,992ZMH1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-MH-22-230: Understanding the role of Gut Immune dysfunction and Gut Microbiome in pathogenesis of Central Nervous System co-morbidities in people living with HIV (R21 Clinical Trial Not Allowed) | ScienceDex | ConductScience